XML 22 R10.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenue Recognition | 6 Months Ended
--- | ---
Jun. 30, 2018
Revenue Recognition [Abstract] |
Revenue Recognition |
5. | Revenue Recognition
Product Sales Our revenue is generated primarily from the sale of products. Product revenue primarily consists of sales of Celution devices and consumables for commercial and research purposes. The Company’s contracts with customers only include one performance obligation (i.e., sale of the Company’s products). Typically, if there are multiple items included on a single order, they are delivered at the same time. Revenue is recognized at a point in time when delivery is completed and control of the promised goods is transferred to the customers. Revenue is measured as the amount of consideration the Company expects to be entitled to in exchange for those goods. The Company’s contracts do not involve financing elements as payment terms with customers are less than one year. The sale arrangements do not include any variable consideration. Advance payments from customers are recorded as deferred revenue. Shipping and handling activities that occur after the customer obtains control of the goods are considered part of the Company’s obligation to transfer the products and therefore are recorded as direct selling expenses, as incurred. The following table represents revenue by product (in thousands):
|  | Three months ended |  | Six months ended |
|  | June 30, 2018 |  |  | June 30, 2017 |  | June 30, 2018 |  |  | June 30, 2017 |
Consumable |  | $ | 594 |  |  | $ | 440 |  | $ | 1,153 |  |  | $ | 949 |
Device |  |  | - |  |  |  | 496 |  |  | 94 |  |  |  | 526 |
Other products |  |  | 66 |  |  |  | 33 |  |  | 144 |  |  |  | 85 |
|  | $ | 660 |  |  | $ | 969 |  | $ | 1,391 |  |  | $ | 1,560 |
Product revenues, classified by geographic location, are as follows (in thousands):
|  | Three months ended |  |  | Six months ended |  |
|  | June 30, 2018 |  |  | June 30, 2017 |  |  | June 30, 2018 |  |  | June 30, 2017 |  |
|  | Product Revenues |  |  | % of Total |  |  | Product Revenues |  |  | % of Total |  |  | Product Revenues |  |  | % of Total |  |  | Product Revenues |  |  | % of Total |  |
Americas |  | $ | 6 |  |  |  | 1 | % |  | $ | 55 |  |  |  | 6 | % |  | $ | 50 |  |  |  | 4 | % |  | $ | 203 |  |  |  | 13 | % |
Japan |  |  | 581 |  |  |  | 88 | % |  |  | 835 |  |  |  | 86 | % |  |  | 1,159 |  |  |  | 83 | % |  |  | 1,155 |  |  |  | 74 | % |
EMEA |  |  | 57 |  |  |  | 9 | % |  |  | 74 |  |  |  | 8 | % |  |  | 148 |  |  |  | 11 | % |  |  | 186 |  |  |  | 12 | % |
Asia Pacific |  |  | 16 |  |  |  | 2 | % |  |  | 5 |  |  |  | 0 | % |  |  | 34 |  |  |  | 2 | % |  |  | 16 |  |  |  | 1 | % |
Total product revenues |  | $ | 660 |  |  |  | 100 | % |  | $ | 969 |  |  |  | 100 | % |  | $ | 1,391 |  |  |  | 100 | % |  | $ | 1,560 |  |  |  | 100 | % |
Concentration of Significant Customers Two direct customers and one distributor comprised 67% of our revenue recognized for the six months ended June 30, 2018. Two direct customers and one distributor accounted for 81% of total outstanding accounts receivable (excluding receivables from the Biomedical Advanced Research Development Authority, a division of the U.S. Department of Health and Human Services (“BARDA”)) as of June 30, 2018. Three direct customers comprised 63% of our revenue recognized for the six months ended June 30, 2017. Two direct customers accounted for 77% of total outstanding accounts receivable as of June 30, 2017. Development Revenue We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA which is outside of the scope of the new revenue recognition guidance. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contracts and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $0.9 million and $1.8 million in development revenue for the three and six months ended June 30, 2018, as compared to $0.5 million and $1.5 million for the three and six months ended June 30, 2017.

X
- Definition The entire disclosure for revenue recognition, which may include a description of accounting policy for product as well as research and development revenue recognition. If there are different policies for different types of revenue transactions, the policy for each material type of transaction should be disclosed. If a sales transaction has multiple element arrangements, the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. + References No definition available. + Details
Name: | cytx_RevenueRecognitionTextBlock
Namespace Prefix: | cytx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration